MPR Weekly Dose 225 — New Vaccine Approvals; Skin Prep Recalled; Insulin Biosimilar Approved; Twice-yearly lenacapavir to be reviewed

New vaccines to protect against meningococcal disease and chikungunya virus; skin prep product recalled due to fungal contamination; rapid-acting insulin biosimilar approved; and twice-yearly lenacapavir gets FDA's priority review for HIV PrEP.

Episode metadata supplied by the publisher feed · Published Feb 20, 2025

Embed this episode

Attribution link and audio player

Ready to play

MPR Weekly Dose 225 — New Vaccine Approvals; Skin Prep Recalled; Insulin Biosimilar Approved; Twice-yearly lenacapavir to be reviewed

0:00 12:48

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of MPR Weekly Dose?

This episode is 12 minutes long.

When was this MPR Weekly Dose episode published?

This episode was published on February 20, 2025.

Can I download this MPR Weekly Dose episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!